The mesh nebulizer segment of the global nebulizer market is expected to witness the forecast period's largest market share. Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Thus it was estimated that mesh nebulizers would be increasingly adopted in the coming future. This is due to the portability, convenience, and speed of treatment, owing to their low residual volumes and accurate lung delivery. Thus, technological advancements in mesh nebulizers, with the development of an innovative solution, are likely further to drive the market's growth in the future.
According to recent facts revealed by the World Health Organization, asthma is the most widespread chronic disease in pediatric populations. Besides, asthma is a global health burden in high-income countries and an economic burden in low- and middle-income populations. The substantial mortality associated with asthma is fueling the demand for better aerosol drug delivery devices in the healthcare sector. The rising number of obese people worldwide who are at increased risk of COPD is also bolstering the demand for mesh nebulizers.
The mesh nebulizer market is estimated to grow at a CAGR of 6.0% during the forecast period (2020-2027)
Market Dynamics
Drivers
- Rising Incidences of Chronic Respiratory Diseases
- Increasing Demand for Home Healthcare Devices
- Rising geriatric population
Restraints
- Side Effects Associated With the Drugs
Market Trends
Future Trends in Nebulized Therapies for Pulmonary Disease:
- Aerosol therapy is a key modality for drug delivery to the lungs of respiratory disease patients. Aerosol therapy improves therapeutic effects by directly targeting diseased lung regions for rapid onset of action, requiring smaller doses than oral or intravenous delivery, and minimizing systemic side effects.
- To optimize the treatment of critically ill patients, the efficacy of aerosol therapy depends on lung morphology, breathing patterns, aerosol droplet characteristics, disease, mechanical ventilation, pharmacokinetics, and the pharmacodynamics of cell-drug interactions.
- While aerosol characteristics are influenced by drug formulations and device mechanisms, most other factors rely on individual patient variables. This has led to increased efforts towards more personalized therapeutic approaches to optimize pulmonary drug delivery and improve the selection of effective drug types for individual patients.
- Vibrating mesh nebulizers (VMN) are the dominant device in clinical trials involving mechanical ventilation and emerging drugs.
- For emerging therapeutics, the use of vibrating mesh nebulizers should prove beneficial to ensure adequate aerosol drug delivery; however, the ultimate efficacy of these drugs in patients has yet to be established.
Nebulizer-based inhalation therapy effecting for COVID-19 Patients:
- Many patients use a home nebulizer for the care of their respiratory conditions. It is essential that a patient with COVID-19 or suspected COVID-19 using a nebulizer at home.
- The National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, is working with regulatory authorities to get approval for a nebulizer-based inhalation therapy designed for use in COVID patients. The inhalation therapy for combating COVID-19 is beneficial.
- In May 2020, the PARI nebulizer was used in a clinical study with Pulmotect's Inhaled PUL-042 for COVID-19.
Geographical Analysis
North America is estimated to account for a share of approximately 41.54% of the inhalation therapy nebulizer market in 2019.
The North American inhalation therapy nebulizer market is growing due to the continuous innovations in technology. As the region's population follows a fast-moving lifestyle, patients are looking for more portable nebulizer devices that can be transferred easily in a time of need for patients who have asthma and other airway diseases. Besides, healthcare cost containment issues and the post-economic crises in the United States have required the government to introduce new strategies to reduce patient stays in hospitals. This provided the impetus to home care services, which created a favorable environment for the nebulizer market's growth.
Moreover, the rising consumption of alcohol, tobacco, ultra-processed products, including sugar-sweetened beverages, is a major cause behind the increasing prevalence of respiratory diseases in North America. According to the Centers for Disease Control and Prevention (CDC) data, about 14% of deaths in adults aged 30 to 70 years in North America are caused due to tobacco consumption. Thus, an increase in the number of smokers and environmental pollution is anticipated to increase nebulizers' demand.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com